Form 4: Boston Scientific SVP, Global Controller and CAO, Emily Woodworth, Reports Stock Transactions
SEC Form 4 Filing
Emily Woodworth, SVP, Global Controller and CAO of Boston Scientific, reports the acquisition and disposal of common stock and derivative securities, including transactions executed under a pre-established Rule 10b5-1 trading plan.
Summary
- On March 3, 2025, Emily Woodworth, SVP, Global Controller and CAO of Boston Scientific, reported transactions involving Boston Scientific common stock.
- These transactions included the acquisition of 5,949 shares of common stock at $37.50 and the disposal of 7,149 shares at a weighted average price of $104.9748.
- On March 4, 2025, Woodworth disposed of 482 shares at $104.63.
- The transactions were executed under a pre-established Rule 10b5-1 trading plan adopted on November 29, 2024.
- Woodworth also reported holding 2,383 stock options with an exercise price of $37.50, granted on February 17, 2021, vesting in four equal annual installments beginning on February 17, 2022.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral. It simply reports transactions.
Positives
- The reporting person's transactions are being conducted under a pre-established Rule 10b5-1 trading plan, which can provide transparency and reduce concerns about insider trading.
Future Outlook
NA
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities. It is common for executives to use Rule 10b5-1 trading plans to manage their stock transactions and avoid potential accusations of insider trading.
Comparison to Industry Standards
- Form 4 filings are standard practice for executives at publicly traded companies like Boston Scientific (BSX).
- Comparable companies such as Medtronic (MDT) and Abbott Laboratories (ABT) also have executives who regularly file Form 4s to report their stock transactions.
- The use of Rule 10b5-1 trading plans is a common strategy among executives in the medical device industry to manage their stock sales in a compliant manner.
Stakeholder Impact
- Shareholders are informed about the insider trading activities of a key executive.
- The filing provides transparency regarding the executive's transactions, which can influence investor confidence.
Key Dates
| Date | Description |
|---|---|
| 2021-02-17 | Grant date of stock options vesting in four equal annual installments beginning on February 17, 2022 |
| 2022-02-17 | First anniversary of the grant date; start of annual vesting installments for stock options |
| 2024-11-29 | Adoption date of the Rule 10b5-1 trading plan |
| 2025-03-03 | Date of common stock acquisition and disposal transactions |
| 2025-03-04 | Date of common stock disposal transaction |
| 2025-03-05 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.